FilingSEC EDGAR6-K
Nasus Pharma Receives FDA Clearance for NS002 Anaphylaxis Clinical Study
· SEC accepted
StageClinical Clearance
Filing content
The company received FDA clearance for its IND application for NS002, an intranasal epinephrine powder, and plans to initiate a pivotal study in the fourth quarter of 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…